Qulipta (atogepant) from AbbVie was first approved by the FDA in September of 2021 for the prevention of episodic migraine, and then in April 2023 for prevention of chronicmigraine headaches. How well does Qulipta work for episodic migraine? The ADVANCE trial was a 12-week long, double-...